Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

CTD2 Dashboard: a searchable web interface to connect validated results from the Cancer Target Discovery and Development Network.

Aksoy BA, DancĂ­k V, Smith K, Mazerik JN, Ji Z, Gross B, Nikolova O, Jaber N, Califano A, Schreiber SL, Gerhard DS, Hermida LC, Jagu S, Sander C, Floratos A, Clemons PA.

Database (Oxford). 2017 Jan 1;2017. doi: 10.1093/database/bax054.

2.

Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.

Kalnin K, Chivukula S, Tibbitts T, Yan Y, Stegalkina S, Shen L, Cieszynski J, Costa V, Sabharwal R, Anderson SF, Christensen N, Jagu S, Roden RBS, Kleanthous H.

Vaccine. 2017 Sep 5;35(37):4942-4951. doi: 10.1016/j.vaccine.2017.07.086. Epub 2017 Aug 1.

3.

Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.

Jagu S, Karanam B, Wang JW, Zayed H, Weghofer M, Brendle SA, Balogh KK, Tossi KP, Roden RBS, Christensen ND.

Vaccine. 2015 Oct 13;33(42):5553-5563. doi: 10.1016/j.vaccine.2015.09.005. Epub 2015 Sep 15.

4.

Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Wang JW, Jagu S, Wu WH, Viscidi RP, Macgregor-Das A, Fogel JM, Kwak K, Daayana S, Kitchener H, Stern PL, Gravitt PE, Trimble CL, Roden RB.

Clin Vaccine Immunol. 2015 Jul;22(7):806-16. doi: 10.1128/CVI.00799-14. Epub 2015 May 13.

5.

Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.

Wang JW, Jagu S, Wang C, Kitchener HC, Daayana S, Stern PL, Pang S, Day PM, Huh WK, Roden RB.

PLoS One. 2014 Jul 7;9(7):e101576. doi: 10.1371/journal.pone.0101576. eCollection 2014.

6.

Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.

Kwak K, Jiang R, Wang JW, Jagu S, Kirnbauer R, Roden RB.

PLoS One. 2014 May 9;9(5):e97232. doi: 10.1371/journal.pone.0097232. eCollection 2014.

7.

Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.

Kalnin K, Tibbitts T, Yan Y, Stegalkina S, Shen L, Costa V, Sabharwal R, Anderson SF, Day PM, Christensen N, Schiller JT, Jagu S, Roden RB, Almond J, Kleanthous H.

Vaccine. 2014 Jun 12;32(28):3540-7. doi: 10.1016/j.vaccine.2014.04.032. Epub 2014 Apr 26.

8.

Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.

Wang JW, Jagu S, Kwak K, Wang C, Peng S, Kirnbauer R, Roden RB.

Virology. 2014 Jan 20;449:304-16. doi: 10.1016/j.virol.2013.10.038. Epub 2013 Dec 20.

9.

Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.

Kwak K, Jiang R, Jagu S, Wang JW, Wang C, Christensen ND, Roden RB.

PLoS One. 2013;8(3):e60507. doi: 10.1371/journal.pone.0060507. Epub 2013 Mar 25.

10.

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.

Jagu S, Kwak K, Schiller JT, Lowy DR, Kleanthous H, Kalnin K, Wang C, Wang HK, Chow LT, Huh WK, Jaganathan KS, Chivukula SV, Roden RB.

J Virol. 2013 Jun;87(11):6127-36. doi: 10.1128/JVI.03218-12. Epub 2013 Mar 27.

11.

Optimization of multimeric human papillomavirus L2 vaccines.

Jagu S, Kwak K, Karanam B, Huh WK, Damotharan V, Chivukula SV, Roden RB.

PLoS One. 2013;8(1):e55538. doi: 10.1371/journal.pone.0055538. Epub 2013 Jan 31.

12.

Capsomer vaccines protect mice from vaginal challenge with human papillomavirus.

Wu WH, Gersch E, Kwak K, Jagu S, Karanam B, Huh WK, Garcea RL, Roden RB.

PLoS One. 2011;6(11):e27141. doi: 10.1371/journal.pone.0027141. Epub 2011 Nov 1.

13.

A multimeric L2 vaccine for prevention of animal papillomavirus infections.

Jagu S, Malandro N, Kwak K, Yuan H, Schlegel R, Palmer KE, Huh WK, Campo MS, Roden RB.

Virology. 2011 Nov 10;420(1):43-50. doi: 10.1016/j.virol.2011.07.020. Epub 2011 Sep 13.

14.

In vivo mechanisms of vaccine-induced protection against HPV infection.

Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, Schiller JT.

Cell Host Microbe. 2010 Sep 16;8(3):260-70. doi: 10.1016/j.chom.2010.08.003.

15.

Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.

Jagu S, Kwak K, Garcea RL, Roden RB.

Vaccine. 2010 Jun 17;28(28):4478-86. doi: 10.1016/j.vaccine.2010.04.039. Epub 2010 Apr 29.

16.

Photonic approach to the selective inactivation of viruses with a near-infrared subpicosecond fiber laser.

Tsen KT, Tsen SW, Fu Q, Lindsay SM, Kibler K, Jacobs B, Wu TC, Karanam B, Jagu S, Roden RB, Hung CF, Sankey OF, Ramakrishna B, Kiang JG.

J Biomed Opt. 2009 Nov-Dec;14(6):064042. doi: 10.1117/1.3275477.

PMID:
20059280
17.

Role of L2 cysteines in papillomavirus infection and neutralization.

Gambhira R, Jagu S, Karanam B, Day PM, Roden R.

Virol J. 2009 Oct 27;6:176. doi: 10.1186/1743-422X-6-176.

18.

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB.

J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. doi: 10.1093/jnci/djp106. Epub 2009 May 26.

19.

Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.

Karanam B, Jagu S, Huh WK, Roden RB.

Immunol Cell Biol. 2009 May-Jun;87(4):287-99. doi: 10.1038/icb.2009.13. Review.

20.

Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2.

Lin Z, Yemelyanova AV, Gambhira R, Jagu S, Meyers C, Kirnbauer R, Ronnett BM, Gravitt PE, Roden RB.

Am J Pathol. 2009 Jan;174(1):136-43. doi: 10.2353/ajpath.2009.080588. Epub 2008 Dec 18.

21.

Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.

Karanam B, Gambhira R, Peng S, Jagu S, Kim DJ, Ketner GW, Stern PL, Adams RJ, Roden RB.

Vaccine. 2009 Feb 11;27(7):1040-9. doi: 10.1016/j.vaccine.2008.11.099. Epub 2008 Dec 16.

22.

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.

Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT, Zeng W, Jackson DC, Roden RB.

Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5850-5. doi: 10.1073/pnas.0800868105. Epub 2008 Apr 14.

23.

A protective and broadly cross-neutralizing epitope of human papillomavirus L2.

Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RB.

J Virol. 2007 Dec;81(24):13927-31. Epub 2007 Oct 10.

24.

Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, Roden RB.

J Virol. 2007 Nov;81(21):11585-92. Epub 2007 Aug 22.

Supplemental Content

Support Center